10 Best Cosmetic Surgery and Aesthetics Stocks To Buy

3. Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Number of Hedge Fund Investors: 41

Revenue Growth Rate (year-over-year): 6.55%

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is a global provider of medical technology, operating through its subsidiaries. The company creates, produces, and sells orthopedic reconstructive products, including knee and hip products.

The previous three months’ modest growth, weak cash flows, and rising interest rates have all contributed to ZBH’s share price struggles. The ROSA robotic surgery system is one of the new products that are being launched to promote growth. Although there are advantages due to changes in population and technology, Stryker’s rivalry still presents difficulties.

A $2 billion stock repurchase program and the company’s emphasis on ASCs are signs of optimism, but dangers include high debt levels and pressure from competitors, especially in China, as well as Stryker’s superior performance.

To demonstrate its dedication to innovation, Zimmer Biomet intends to introduce close to 30 fresh products this year, with over 50 more in the long-term plan.

RevelAi Health and Zimmer Biomet Holdings, Inc. (NYSE) teamed up to commercialize RevelAi’s patient care management system and improve orthopedic treatment with AI. AI can help improve healthcare operations and lessen burnout among doctors, according to CEO Christian Péan.

The clinician-guided voice agent and text messaging features of RevelAi’s technology streamline operations while satisfying Centers for Medicare & Medicaid Services (CMS) criteria. Edmond Davis, Senior Director, the Health Equity Division of Zimmer Biomet, emphasized the company’s dedication to providing underprivileged populations with access to orthopedic care.

To improve its ROSA Robotics suite, Zimmer Biomet and THINK Surgical inked an exclusive distribution deal for the TMINI Miniature Robotic System. The TMINI system, which promises to increase knee implant placement accuracy, will be ready in late 2024.

Following a discussion with an orthopedic physician acquainted with the company’s most recent product offerings, such as Persona IQ and OsseoTi cementless, TD Cowen decided to maintain Zimmer Biomet at a Hold rating, with a $143.00 price target.

As of the end of the first quarter of 2024, 41 hedge funds out of the 920 funds reported having stakes in Zimmer Biomet Holdings, Inc. (NYSE:ZBH). The company’s top shareholder is John Murphy’s Levin Easterly Partners which has 72,717 shares worth $7.89 million.